Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2337/dbi24-0050 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diabetes Spotlight: A New Addition to the Journal.
Diabetes
February 2025
Division of Endocrinology and Metabolism, Department of Medicine, Duke University Medical Center, Durham, NC.
Current approaches in CRISPR-Cas systems for diabetes.
Prog Mol Biol Transl Sci
January 2025
R and D, Salem Microbes Private Limited, Salem, Tamil Nadu, India. Electronic address:
In the face of advancements in health care and a shift towards healthy lifestyle, diabetes mellitus (DM) still presents as a global health challenge. This chapter explores recent advancements in the areas of genetic and molecular underpinnings of DM, addressing the revolutionary potential of CRISPR-based genome editing technologies. We delve into the multifaceted relationship between genes and molecular pathways contributing to both type1 and type 2 diabetes.
View Article and Find Full Text PDFHepatic metabolism and ketone production in metabolic dysfunction-associated steatotic liver disease.
Curr Opin Gastroenterol
January 2025
Department of Nutrition Sciences.
Purpose Of Review: Metabolic dysfunction-associated steatotic liver disease (MASLD) is present in 25-35% of individuals in the United States. The purpose of this review is to provide the contextual framework for hepatic ketogenesis in MASLD and to spotlight recent advances that have improved our understanding of the mechanisms that drive its development and progression.
Recent Findings: Traditionally, hepatic ketogenesis has only been considered metabolically during prolonged fasting/starvation or with carbohydrate deplete ketogenic diets where ketones provide important alternative energy sources.
Spotlight on the Mechanism of Action of Semaglutide.
Curr Issues Mol Biol
December 2024
1st Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, 11527 Athens, Greece.
Initially intended to control blood glucose levels in patients with type 2 diabetes, semaglutide, a potent glucagon-like peptide 1 analogue, has been established as an effective weight loss treatment by controlling appetite. Integrating the latest clinical trials, semaglutide in patients with or without diabetes presents significant therapeutic efficacy in ameliorating cardiometabolic risk factors and physical functioning, independent of body weight reduction. Semaglutide may modulate adipose tissue browning, which enhances human metabolism and exhibits possible benefits in skeletal muscle degeneration, accelerated by obesity and ageing.
View Article and Find Full Text PDFTFPI2 hypermethylation promotes diabetic atherosclerosis progression through the Ap2α/PPARγ axis.
J Mol Cell Cardiol
January 2025
Department of Cardiology, The Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Qingdao 266003, Shandong, China. Electronic address:
Article Synopsis
- - Diabetes significantly increases the risk of atherosclerosis, causing serious cardiovascular problems, with research showing that the protein TFPI2 is expressed at lower levels in atherosclerotic plaques of diabetic patients.
- - Experiments demonstrated that knocking down TFPI2 in non-diabetic mice led to more severe plaque buildup and increased inflammation, while boosting TFPI2 in diabetic mice improved plaque stability and promoted beneficial M2 macrophage activity.
- - The study reveals that the interaction between TFPI2 and a transcription factor called AP-2α is essential for regulating inflammation and plaque stability in diabetes, suggesting that targeting this pathway could be a novel way to treat diabetes-related cardiovascular diseases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!